P. Kostenuik

Molecular Biology · 2000–2012

A researcher in the Science corpus: 6 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 46 citations into it
• Oncology — 45 citations into it

Whom P. Kostenuik trusts

Their strongest outbound trust, strongest first, inferred from their citations.

1. F. Ross (in Molecular Biology)
2. S. Teitelbaum (in Molecular Biology)

Papers from P. Kostenuik's perspective

Ordered by how strongly the researchers P. Kostenuik trusts endorse each paper. Same corpus, a different order for every researcher.

1. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. (Journal of Clinical Investigation)
2. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). (Human Molecular Genetics)
3. IL-1 mediates TNF-induced osteoclastogenesis. (Journal of Clinical Investigation)
4. Denosumab in postmenopausal women with low bone mineral density. (New England Journal of Medicine)
5. Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength (Journal of Bone and Mineral Research)
6. Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors* (Journal of Biological Chemistry)
7. Bone resorption by osteoclasts. (Science)
8. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. (Journal of Clinical Investigation)
9. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. (Proceedings of the National Academy of Sciences of the United States of America)
10. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. (Journal of Clinical Investigation)

Their papers

• Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis (2009) — 773 citations
• Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis (2000) — 599 citations
• Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab (2012) — 645 citations
• Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength (2008) — 956 citations
• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. (2008) — 800 citations
• RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. (2000) — 1,176 citations